Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure

Part of the Current Cardiovascular Therapy book series (CCT, volume 5)


Blood pressure (BP)-lowering is a cornerstone of cardiovascular risk reduction in patients with hypertension and heart failure (HF). Antihypertensive agents recommended by current international guidelines for such individuals include angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers and diuretic agents. However, as high proportions of patients with HF suffer simultaneously from other co-morbidities such as chronic kidney disease (CKD) and/or diabetes, selection of the appropriate antihypertensive regimen should take into account the specific indications and contraindications of antihypertensive drugs and combinations in patients with CKD as well as the diverse effects of different antihypertensive drug classes on glucose metabolism. ACEIs and ARBs represent the drugs of first choice for patients with diabetic nephropathy or non-diabetic proteinuric kidney disease, but in patients with non-diabetic CKD without proteinuria they have no specific indication. Furthermore, the ACEI and ARB combination was associated with adverse renal effects in recent clinical trials. With regards to the metabolic effects of antihypertensive drugs, older β-blockers and diuretic agents were shown to deteriorate insulin sensitivity and to elevate the risk of new-onset diabetes, while ACEIs and ARBs have neutral or even beneficial impact on glucose metabolism. This chapter will discuss currently available clinical evidence on the effect of antihypertensive treatment on kidney disease progression and on metabolic profile, aiming to offer insights on the choice of the appropriate BP-lowering regimen in patients with HF in the presence of CKD and/or diabetes.


Heart failure Chronic kidney disease Diabetes Antihypertensive treatment Renal outcomes Metabolic profile 


  1. 1.
    Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–319.PubMedGoogle Scholar
  2. 2.
    Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–245.PubMedGoogle Scholar
  3. 3.
    Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001–2005. Arch Intern Med. 2008;168:2481–8.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994–2003. Arch Intern Med. 2008;168:418–24.PubMedGoogle Scholar
  5. 5.
    Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101:1016–22.PubMedGoogle Scholar
  6. 6.
    Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.PubMedGoogle Scholar
  7. 7.
    Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.PubMedGoogle Scholar
  8. 8.
    Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:1–290.Google Scholar
  9. 9.
    Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int. 2014;85(3):536–46.PubMedGoogle Scholar
  10. 10.
    Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.PubMedGoogle Scholar
  11. 11.
    Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.PubMedGoogle Scholar
  12. 12.
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–7.PubMedGoogle Scholar
  13. 13.
    Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007;25:249–52.PubMedGoogle Scholar
  14. 14.
    Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007;7:191–9.PubMedGoogle Scholar
  15. 15.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.PubMedGoogle Scholar
  16. 16.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.PubMedGoogle Scholar
  17. 17.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.PubMedGoogle Scholar
  18. 18.
    Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828–38.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21:922–9.PubMedGoogle Scholar
  20. 20.
    De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–20.PubMedGoogle Scholar
  21. 21.
    Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–7.PubMedGoogle Scholar
  22. 22.
    The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.Google Scholar
  23. 23.
    Wright Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.PubMedGoogle Scholar
  24. 24.
    Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–40.PubMedGoogle Scholar
  25. 25.
    Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.PubMedGoogle Scholar
  26. 26.
    Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165:947–53.PubMedGoogle Scholar
  27. 27.
    Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.PubMedGoogle Scholar
  28. 28.
    Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–52.PubMedGoogle Scholar
  29. 29.
    Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198–202.PubMedGoogle Scholar
  30. 30.
    Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.PubMedGoogle Scholar
  31. 31.
    Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004;24:168–75.PubMedGoogle Scholar
  32. 32.
    Stafilas PC, Sarafidis PA, Lasaridis AN, Aletras VH, Niakas DA. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. Am J Hypertens. 2005;18:1233–40.PubMedGoogle Scholar
  33. 33.
    Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–8.PubMedGoogle Scholar
  34. 34.
    O’Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150:717–24.PubMedGoogle Scholar
  35. 35.
    Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–33.PubMedGoogle Scholar
  36. 36.
    de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet. 2006;367:899–900.PubMedGoogle Scholar
  37. 37.
    Mann JF, McClellan WM, Kunz R, Ritz E. Progression of renal disease – can we forget about inhibition of the renin-angiotensin system? Nephrol Dial Transplant. 2006;21:2348–51.PubMedGoogle Scholar
  38. 38.
    Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:12–26.PubMedGoogle Scholar
  39. 39.
    Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–46.PubMedGoogle Scholar
  40. 40.
    Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23 Suppl 2:B54–64.PubMedGoogle Scholar
  41. 41.
    Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–81.PubMedGoogle Scholar
  42. 42.
    Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190–8.PubMedGoogle Scholar
  43. 43.
    Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16:3038–45.PubMedGoogle Scholar
  44. 44.
    Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921–6.PubMedGoogle Scholar
  45. 45.
    Schjoedt KJ, Astrup AS, Persson F, et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia. 2009;52:46–9.PubMedGoogle Scholar
  46. 46.
    Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–4.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002;25:95–100.PubMedGoogle Scholar
  48. 48.
    Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–24.PubMedGoogle Scholar
  49. 49.
    Retraction – combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2009;374:1226.Google Scholar
  50. 50.
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedGoogle Scholar
  51. 51.
    Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008;372:511–2.PubMedGoogle Scholar
  52. 52.
    Ruilope LM, Segura J, Zamorano JL. New clinical concepts after the ONTARGET trial. Expert Rev Cardiovasc Ther. 2011;9:685–9.PubMedGoogle Scholar
  53. 53.
    Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46.PubMedGoogle Scholar
  54. 54.
    Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol. 2011;6:1025–31.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Novartis announces termination of ALTITUDE study with Rasilez®/Tekturna® in high-risk patients with diabetes and renal impairment. 4-1-2012. information-center/20111220-rasilez-tekturna.pdf. Accessed 4 January 2012.
  56. 56.
    Sarafidis PA, Bakris GL. Addition of renin-inhibitor in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014;15(1):97–8.PubMedGoogle Scholar
  57. 57.
    Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1–9.PubMedGoogle Scholar
  58. 58.
    Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000;58:2084–92.PubMedGoogle Scholar
  59. 59.
    Chrysostomou A, Pedagogos E, MacGregor L, Becker G. Aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1:256–62.PubMedGoogle Scholar
  60. 60.
    Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106–12.PubMedGoogle Scholar
  61. 61.
    Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–36.PubMedGoogle Scholar
  62. 62.
    Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–42.PubMedGoogle Scholar
  63. 63.
    Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–8.PubMedGoogle Scholar
  64. 64.
    Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641–50.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012;7:1234–41.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.PubMedGoogle Scholar
  67. 67.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.PubMedGoogle Scholar
  68. 68.
    Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens. 1995;9:137–41.PubMedGoogle Scholar
  69. 69.
    Prince MJ, Stuart CA, Padia M, Bandi Z, Holland OB. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. Arch Intern Med. 1988;148:2363–8.PubMedGoogle Scholar
  70. 70.
    Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226–30.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia. 1995;38:853–9.PubMedGoogle Scholar
  72. 72.
    Hunter SJ, Harper R, Ennis CN, et al. Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension. J Hypertens. 1998;16:103–9.PubMedGoogle Scholar
  73. 73.
    Hunter SJ, Wiggam MI, Ennis CN, et al. Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet Med. 1999;16:482–7.PubMedGoogle Scholar
  74. 74.
    Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8:351–6.Google Scholar
  75. 75.
    Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 1994;43:455–61.PubMedGoogle Scholar
  76. 76.
    Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489–94.PubMedGoogle Scholar
  77. 77.
    Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.PubMedGoogle Scholar
  78. 78.
    Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955–9.PubMedGoogle Scholar
  79. 79.
    Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19:1429–35.PubMedGoogle Scholar
  80. 80.
    Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795–801.PubMedGoogle Scholar
  81. 81.
    Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997;11:753–7.PubMedGoogle Scholar
  82. 82.
    Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24:1397–403.PubMedGoogle Scholar
  83. 83.
    Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893–8.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 1987;17:448–54.PubMedGoogle Scholar
  85. 85.
    Suzuki M, Ikebuchi M, Yokota C, Shinozaki K, Harano Y. Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens. 1995;17:1257–68.PubMedGoogle Scholar
  86. 86.
    Zebekakis P, Kopras A, Lasaridis AN, et al. Α comparative study of the effects of amlodipine and fosinopril on blood pressure and insulin sensitivity in hypertensive patients. J Hypertens. 2003;21:S71.Google Scholar
  87. 87.
    Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens. 1996;9:323–33.PubMedGoogle Scholar
  88. 88.
    Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens. 1999;12:298–303.PubMedGoogle Scholar
  89. 89.
    Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med. 2006;119:S24–30.PubMedGoogle Scholar
  90. 90.
    Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993–1002.PubMedGoogle Scholar
  91. 91.
    Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels – a systematic review. Blood Press. 2006;15:135–50.PubMedGoogle Scholar
  92. 92.
    Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005;4:6.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Sarafidis PA, Lasaridis AN, Hatzistavri L, Zebekakis P, Tziolas I. The effect of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients. Rev Clin Pharmacol Pharmacokin (Int Ed). 2004;18:60–6.Google Scholar
  94. 94.
    Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006;55:1159–64.PubMedGoogle Scholar
  95. 95.
    Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55:1149–54.PubMedGoogle Scholar
  96. 96.
    Grassi G, Seravalle G, Dell’Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761–9.PubMedGoogle Scholar
  97. 97.
    Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–6.PubMedGoogle Scholar
  98. 98.
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–72.PubMedGoogle Scholar
  99. 99.
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedGoogle Scholar
  100. 100.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.Google Scholar
  101. 101.
    Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting – enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–92.PubMedGoogle Scholar
  102. 102.
    Reid CM, Johnston CI, Ryan P, WilLson K, Wing LM. Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study. Am J Hypertens. 2003;16:11A.Google Scholar
  103. 103.
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedGoogle Scholar
  104. 104.
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.PubMedGoogle Scholar
  105. 105.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.PubMedGoogle Scholar
  106. 106.
    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.PubMedGoogle Scholar
  107. 107.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.Google Scholar
  108. 108.
    Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care. 2004;27:247–55.PubMedGoogle Scholar
  109. 109.
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–6.PubMedGoogle Scholar
  110. 110.
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–65.PubMedGoogle Scholar
  111. 111.
    Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.PubMedGoogle Scholar
  112. 112.
    Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561–72.PubMedGoogle Scholar
  113. 113.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.PubMedGoogle Scholar
  114. 114.
    Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:1405–12.PubMedGoogle Scholar
  115. 115.
    Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563–74.PubMedGoogle Scholar
  116. 116.
    Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592–7.PubMedGoogle Scholar
  117. 117.
    Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–62.PubMedGoogle Scholar
  118. 118.
    Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–9.PubMedGoogle Scholar
  119. 119.
    Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29–35.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Nephrology, “Hippokration” General HospitalAristotle University of ThessalonikiThessalonikiGreece
  2. 2.Section of Nephrology and Hypertension, 1st Department of MedicineAristotle University of Thessaloniki, AHEPA University HospitalThessalonikiGreece
  3. 3.Department of CardiologyAsklepeion General HospitalAthensGreece

Personalised recommendations